US Stock MarketDetailed Quotes
XFOR X4 Pharmaceuticals
- 0.475
- -0.090-15.96%
Trading Jan 14 14:15 ET
81.03MMarket Cap-5.94P/E (TTM)
0.570High0.465Low3.09MVolume0.570Open0.565Pre Close1.53MTurnover2.38%Turnover RatioLossP/E (Static)170.55MShares1.60052wk High1.36P/B61.72MFloat Cap0.26152wk Low--Dividend TTM129.91MShs Float23.930Historical High--Div YieldTTM18.59%Amplitude0.261Historical Low0.496Avg Price1Lot Size
X4 Pharmaceuticals Stock Forum
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you d...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you d...
50
20
9
$X4 Pharmaceuticals (XFOR.US)$
I believe this will go up it just needs a little time. I have a position still.
I believe this will go up it just needs a little time. I have a position still.
2
1
$X4 Pharmaceuticals (XFOR.US)$
X4 Pharmaceuticals Inc - to Submit Maa to EMA for Mavorixafor in Whim Syndrome
X4 Pharmaceuticals Inc - to Submit Maa to EMA for Mavorixafor in Whim Syndrome
$X4 Pharmaceuticals (XFOR.US)$
X4 Pharmaceuticals Inc - to Receive €28.5 Mln Upfront, up to €226 Mln in Milestones
X4 Pharmaceuticals Inc - to Receive €28.5 Mln Upfront, up to €226 Mln in Milestones
$X4 Pharmaceuticals (XFOR.US)$
X4 Pharmaceuticals and Norgine Enter Into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
X4 Pharmaceuticals and Norgine Enter Into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
$X4 Pharmaceuticals (XFOR.US)$ Reuters· 1 min ago
X4 Pharmaceuticals and Norgine Enter Into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
X4 Pharmaceuticals and Norgine Enter Into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
1
$X4 Pharmaceuticals (XFOR.US)$
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
Monday, 13th January at 7:35 am
X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the mid-twenties
Upfront non-dilutive funds strengthen X4's balance sheet as enrollment ramps up in the company's gl...
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
Monday, 13th January at 7:35 am
X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the mid-twenties
Upfront non-dilutive funds strengthen X4's balance sheet as enrollment ramps up in the company's gl...
1
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
李飞Allyssa : Doctor, can you please take a look at LAES?
Jaguar8 OP 李飞Allyssa : Sorry I forgot haha WKEY and LAES are together
李飞Allyssa : Hope it rebounds tomorrow, thank you very much for your efforts![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
152390662 : May I ask where did you see the announcement for $LeddarTech (LDTC.US)$
Jaguar8 OP 152390662 : QUEBEC CITY, Canada, Jan. 13, 2025 (GLOBE NEWSWIRE) -- LeddarTech® Holdings Inc. (“LeddarTech”) (Nasdaq: LDTC), an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology, LeddarVision
, today announced it has wrapped up its presence at the 2025 Consumer Electronics Show (CES) and achieved key strategic milestones. The culmination of the event demonstrates that the company is poised to deliver exceptional value to its customers.
Driving Innovation Through Strategic Partnerships
With the successful CES 2025 demonstration of LeddarVision Surround (LVS-2+) software utilizing Texas Instruments (“TI”) TDA4VH-Q1 processor, LeddarTech has now received the second advanced royalty payment of US$ 3 million as part of its licensing agreement. This partnership, announced in early December 2024, aims to capitalize on the integration of LeddarTech’s groundbreaking LeddarVision software into TI’s scalable portfolio of processors to create a comprehensive platform for advanced driver assistance systems (ADAS) and autonomous driving (AD) markets. The collaboration signifies a pivotal step forward in delivering cutting-edge solutions to automotive OEMs and Tier 1 suppliers, underscoring LeddarTech’s commitment to innovation and leadership.
Customer and Partner Enthusiasm at CES 2025
At CES 2025 in Las Vegas, LeddarTech showcased its LeddarVision Surround-View (LVS-2+), a state-of-the-art software stack tailored for L2/L2+ highway and city ADAS applications. This breakthrough technology addresses critical challenges the automotive industry faces, setting new benchmarks in safety and performance and enabling automotive manufacturers to cost-effectively meet 5-star NCAP 2025/GSR 2022 requirements.
View more comments...